Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 2Sarcoma 1Osteosarcoma 1Melanoma 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Bone Neoplasms 1

Interventions

pembrolizumab 18Nivolumab 13avelumab 10Ipilimumab 7Specimen Handling 6cemiplimab 5atezolizumab 5Magnetic Resonance Spectroscopy 5Biopsy 5Radiotherapy 3Cyclophosphamide 3prednylidene 2poly ICLC 2lutetium Lu 177 dotatate 2fludarabine phosphate 2fludarabine 2durvalumab 2deltacortene 2aldesleukin 2Radiosurgery 2Prednisone 2Interleukin-2 2Immunoglobulin G 2Docetaxel 2CTLA-4 Antigen 2Bevacizumab 2tocilizumab 1talimogene laherparepvec 1sargramostim 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Merkel Cell × flt3 ligand protein × 1 year × Clear all
NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

University of Southern California

Phase 1 Active not recruiting
14 enrolled
BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡